$295.03
Value $522B
AbbVievsEntrada Therapeutics
ABBV and TRDA stock compared: price, dividend, valuation and results, from SEC filings.
+0.20%
$5.09
Value $195M
AbbVie (ABBV) has a market value of $522B and Entrada Therapeutics (TRDA) $195M. Over the last year, with dividends, ABBV moved +30.3% and TRDA -36.5%. Dividend yield: ABBV 2.35%, TRDA none.
At a glance
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABBV$522B
TRDA$195M
ABBV is 2,677 times TRDA
Revenue, 12 months
ABBV$66.0B
TRDA$4.0M
ABBV is 16,599 times TRDA
Net income, 12 months
ABBV$10.3B
TRDA-$161M
Operating margin
ABBV32.2%
TRDA-4,303.8%
4,336.0 points apart
ROIC
ABBV25.7%
TRDA-50.1%
75.8 points apart
P/E
ABBV50.7
TRDA–
Dividend yield
ABBV2.4%
TRDA0.0%
2.4 points apart
5-year return
ABBV+201.5%
TRDA-84.3%
285.8 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
The price over time
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABBV+201.5%
TRDA-84.3%
| Period | ABBVWith dividends | TRDAWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +30.3%Price +26.5% | -36.5%Price -36.5% |
| 3 years since November 13, 2023 | +135.3%+33.0% a yearPrice +112.8% | -68.9%-32.3% a yearPrice -68.9% |
| 5 years since November 12, 2021 | +201.5%+24.7% a yearPrice +152.2% | -84.3%-30.9% a yearPrice -84.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
Every figure
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABBVAbbVieTRDAEntrada Therapeutics
Valuation
ABBVTRDA| Price | $295.03 | $5.09 |
|---|---|---|
| Market value | $522B | $195M |
| Enterprise value (EV) | $592B | $1.9M |
| P/E | 50.7 | – |
| P/E, 5-year median | 57.0 | – |
| P/B | – | 1.0 |
| EV/EBIT | 27.9 | – |
| Free cash flow yield | 3.6% | – |
Results and growth
ABBVTRDA| Revenue, 12 months | $66.0B | $4.0M |
|---|---|---|
| Net income, 12 months | $10.3B | -$161M |
| Free cash flow, 12 months | $18.9B | -$136M |
| Earnings per share, 12 months | $5.81 | -$3.84 |
| Revenue growth, year on year | 8.6% | -87.9% |
| Revenue growth a year, past | +5.9%over 5 years | -55.6%over 2 years |
| EPS growth a year, past | -2.8%over 5 years | – |
Margins and returns on capital
ABBVTRDA| Gross margin | 73.7% | – |
|---|---|---|
| Operating margin | 32.2% | -4,303.8% |
| Net margin | 15.7% | -4,058.0% |
| ROIC | 25.7% | -50.1% |
| ROE | – | -59.8% |
Balance sheet
ABBVTRDA| Cash | $10.8B | $193M |
|---|---|---|
| Total debt | $80.9B | $47M |
| Net debt / EBITDA | 3.2 | – |
| Interest cover | 7.1× | – |
Dividends and buybacks
ABBVTRDA| Dividend yield | 2.4% | – |
|---|---|---|
| Dividend per share, 12 months | $6.92 | – |
| Dividend growth a year, past | +6.6%over 5 years | – |
| Buyback yield | 0.2% | – |
| Shareholder yield | 2.5% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
Which is bigger, AbbVie or Entrada Therapeutics?
By market value, AbbVie ($522B) is about 2,677.0 times Entrada Therapeutics ($195M), at today's prices.
How did ABBV and TRDA stock do over the last 5 years?
Since November 12, 2021, ABBV's price moved +152.2% and TRDA's -84.3%. With dividends: ABBV +201.5% (+24.7% a year), TRDA -84.3% (-30.9% a year). Past returns do not predict future ones.
Which pays the higher dividend, ABBV or TRDA?
The dividend yield at today's price is 2.35% for AbbVie and none for Entrada Therapeutics. Over the last twelve months they paid $6.92 and – per share.
Which has the higher profit margins, AbbVie or Entrada Therapeutics?
Over the last twelve months, the net margin was 15.7% for AbbVie and -4,058.0% for Entrada Therapeutics, and the operating margin 32.2% and -4,303.8%. Revenue was $66.0B and $4.0M.
Which is the better investment, AbbVie or Entrada Therapeutics?
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
Other comparisons
With each of the two, and with the largest in its sector.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.
Descriptive data from SEC filings and market prices.